Pius Fasinu

Dr. Pius Fasinu

Campbell University
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Pius FasinuPius Fasinu
Pius Fasinu
PBPatrick J. Bouic
Patrick J. Bouic
BRBernd Rosenkranz
Bernd Rosenkranz
Despite the lack of sufficient information on the safety of herbal products, their use as alternative and/or complementary medicine is globally popular. There is also an increasing interest in medicinal herbs as precursor for pharmacological actives. Of serious concern is the concurrent consumption of herbal products and conventional drugs. Herb–drug interaction (HDI) is the single most important clinical consequence of this practice. Using a structured assessment procedure, the evidence of HDI presents with varying degree of clinical significance. While the potential for HDI for a number of herbal products is inferred from non-human studies, certain HDIs are well established through human studies and documented case reports. Various mechanisms of pharmacokinetic HDI have been identified and include the alteration in the gastrointestinal functions with consequent effects on drug absorption; induction and inhibition of metabolic enzymes and transport proteins; and alteration of renal excretion of drugs and their metabolites. Due to the intrinsic pharmacologic properties of phytochemicals, pharmacodynamic HDIs are also known to occur. The effects could be synergistic, additive, and/or antagonistic. Poor reporting on the part of patients and the inability to promptly identify HDI by health providers are identified as major factors limiting the extensive compilation of clinically relevant HDIs. A general overview and the significance of pharmacokinetic and pharmacodynamic HDI are provided, detailing basic mechanism, and nature of evidence available. An increased level of awareness of HDI is necessary among health professionals and drug discovery scientists. With the increasing number of plant-sourced pharmacological actives, the potential for HDI should always be assessed in the non-clinical safety assessment phase of drug development process. More clinically relevant research is also required in this area as current information on HDI is insufficient for clinical applications.

7 April 2011 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Open access
PDF file
Pius FasinuPius Fasinu
Pius Fasinu
VPViness Pillay
Viness Pillay
VNValence M. K. Ndesendo
Valence M. K. Ndesendo
LTLisa du Toit
Lisa du Toit
Yahya ChoonaraYahya Choonara
Yahya Choonara
In conscious and co‐operating patients, oral drug delivery remains the preferable route of drug administration. However, not all drugs possess the desirable physicochemical and pharmacokinetic properties which favor oral administration mainly due to poor bioavailability. This has in some cases led to the choice of other routes of administration, which may compromise the convenience and increase the risk of non‐compliance. Poor bioavailability has necessitated the administration of higher than normally required oral doses which often leads to economic wastages, risk of toxicity, erratic and unpredictable responses. The challenge over the years has been to design techniques that will allow oral administration of most drugs, irrespective of their properties, to achieve a therapeutic systemic availability. This will be a worthy achievement since over 90% of therapeutic compounds are known to possess oral bioavailability limitations. In this review, an attempt has been made to explore various approaches that have been used in recent years to improve oral drug bioavailability, including physical and chemical means. This review strives to provide a comprehensive overview of advances made over the past 10 years (2000–2010) in the improvement of the oral bioavailability of drugs. Briefly, the design of prodrugs to bypass metabolism or to enhance solubility as well as modification of formulation techniques such as the use of additives, permeation enhancers, solubilizers, emulsifiers and non‐aqueous vehicles have been discussed. Arising approaches, such as formulation modification techniques; novel drug delivery systems, which exploit the gastrointestinal regionality of drugs, and include the pharmaceutical application of nanotechnology as an emerging area in drug delivery; inhibition of efflux pumps; and inhibition of presystemic metabolism have been more extensively addressed. This critical review sought to assess each method aimed at enhancing the oral bioavailability of drugs in terms of the purpose, scientific basis, limitations, commercial application, as well as the areas in which current research efforts are being focused and should be focused in the future. Copyright © 2011 John Wiley & Sons, Ltd.

10 June 2016 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
Pius FasinuPius Fasinu
Pius Fasinu
SPSarah Phillips
Sarah Phillips
MEMahmoud A. ElSohly
Mahmoud A. ElSohly
LWLarry A. Walker
Larry A. Walker

13 January 2014 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
CACharles Awortwe
Charles Awortwe
Pius FasinuPius Fasinu
Pius Fasinu
BRB. Rosenkranz
B. Rosenkranz
The Caco-2 model is employed in pre-clinical investigations to predict the likely gastrointestinal permeability of drugs because it expresses cytochrome P450 enzymes, transporters, microvilli and enterocytes of identical characteristics to the human small intestine. The FDA recommends this model as integral component of the Biopharmaceutics Classification System (BCS). Most dedicated laboratories use the Caco-2 cell line to screen new chemical entities through prediction of its solubility, bioavailability and the possibility of drug-drug or herb-drug interactions in the gut lumen. However, challenges in the inherent characteristics of Caco-2 cell and inter-laboratory protocol variations have resulted to generation of irreproducible data. These limitations affect the extrapolation of data from pre-clinical research to clinical studies involving drug-drug and herb-drug interactions. This review addresses some of these caveats and enumerates the plausible current and future approaches to reduce the anomalies associated with Caco-2 cell line investigations focusing on its application in herb-drug interactions. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

30 June 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
Pius FasinuPius Fasinu
Pius Fasinu
OOOrish Ebere Orisakwe
Orish Ebere Orisakwe
Heavy Metal Pollution in Sub-Saharan Africa and Possible Implications in Cancer Epidemiology Cancer;environmental pollution;heavy metals;sub-Saharan Africa;epidemiology; The increasing scourge of cancer epidemiology is a global concern. With WHO emphasizing that 40% of all cancer cases are preventable, exposure to known and suspected carcinogens must be discouraged. The battle with communicable diseases and other third world challenges has greatly de-emphasized anti-cancer campaigns in sub-Saharan Africa. The abundant deposit of mineral resources in sub-Saharan Africa has attracted high mining activity with its negative environmental aftermath. Poor regulatory mechanisms have led to environmental contamination by products of mining including heavy metals. In addition to poor urban planning, the springing up of settlements in industrial areas has led to generation and exposure to more hazardous wastes consequent on poor disposal systems. Studies establishing close association between exposure to heavy metals and cancer epidemiology in sub-Saharan Africa are increasing. The current review assesses the level of environmental pollution by heavy metals in sub-Saharan Africa, and brings to the fore available evidence implicating such in the increasing cancer epidemiology in the sub-continent.

1 February 2012 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
Pius FasinuPius Fasinu
Pius Fasinu
PBPatrick J. Bouic
Patrick J. Bouic
BRBernd Rosenkranz
Bernd Rosenkranz
Early understanding of the metabolic pathway and potential interaction of new drug candidates with other drugs is one of the goals of preclinical studies in the drug discovery process. Although other body organs are involved in drug biotransformation, the liver is the predominant organ of metabolism for a wide range of endogenous compounds and xenobiotics. The set of enzymes contained in the cytochrome P450 superfamily present predominantly in the liver have been identified as the single most important agent of drug metabolism and have formed the bedrock of most matured technologies for in vitro drug biotransformation studies. With the development of a number of liver-based technologies, in vitro metabolism has gained significant popularity in the past three decades. This has come in response to several demanding factors including the questionable relevance of data from animal studies; the high cost and stringent regulatory and ethical requirement, as well as safety issues involved with studies using human subjects; and the need for high throughput due to the wide range of chemical entities for routine investigations. These technologies which vary from whole liver to subcellular fractions have found ready application in generating the desired information on the substrate and inhibitor specificity of most metabolic enzymes. This paper reviews such technologies as isolated fresh liver; liver slices; primary, cultured and cryopreserved hepatocytes; microsomes; cytosolic fractions; and purified or heterologously expressed drug-metabolizing enzymes. It highlights the general principles of in vitro enzyme kinetics and the factors that determine the choice of each in vitro technology for biotransformation studies.